<DOC>
	<DOCNO>NCT02501629</DOCNO>
	<brief_summary>The primary objective study determine ability reslizumab administer sc produce corticosteroid-sparing effect patient oral corticosteroid ( OCS ) -dependent asthma elevate blood eosinophil , without loss asthma control .</brief_summary>
	<brief_title>An Efficacy Safety Study Reslizumab Subcutaneous Patients With Oral Corticosteroid Dependent Asthma Elevated Blood Eosinophils</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>1 . The patient male female , 12 year age old , previous diagnosis asthma . 2 . Written inform consent obtain . 3 . The patient require daily maintenance dose prednisone equivalent asthma 5 40 mg 3 month prior screen . 4 . The patient document elevated blood eosinophil screen previous 12 month . 5 . The patient require high dose ICS plus another asthma controller least 6 month prior screen . 6 . The patient FEV1 reversibility inhale SABA historical reversibility within previous 24 month . Other criterion may apply , please contact investigator information . 1 . The patient clinically significant , uncontrolled medical condition would interfere study schedule procedure interpretation efficacy result would compromise patient 's safety . 2 . The patient another confound underlying lung disorder . 3 . The patient know hypereosinophilic syndrome . 4 . The patient history malignancy within 5 year screen visit , except treat cured nonmelanoma skin cancer . 5 . The patient pregnant intend become pregnant study lactate . 6 . The patient require treatment asthma exacerbation within 4 week screen . 7 . The patient current smoker smoke history â‰¥10 packyears . 8 . The patient currently use systemic immunosuppressive immunomodulatory biologic except maintenance OCS treatment asthma . 9 . The patient participate clinical study within 30 day 5 halflives investigational drug screening , whichever longer . 10 . The patient previously expose benralizumab within 12 month screen . 11 . The patient previously expose reslizumab . 12 . The patient history immunodeficiency disorder include human immunodeficiency virus . 13 . The patient current suspect drug and/or alcohol abuse . 14 . The patient active helminthic parasitic infection treat one within 6 month screen . 15 . The patient history allergic reaction hypersensitivity component study drug . Other criterion may apply , please contact investigator information .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>